Serum Tumour Markers Package

Serum Tumour Markers Package is a specialized diagnostic suite designed to identify specific proteins, antigens, or hormones produced by cancer cells or by the body in response to cancer. This profile is an essential resource for high-risk screening, evaluating treatment efficacy, and monitoring for potential recurrence.

CA 125 (Ovarian Cancer Marker): Cancer Antigen 125 is a protein primarily used to monitor the treatment of ovarian cancer. While it can be elevated in non-cancerous conditions (such as endometriosis or pelvic inflammatory disease), it remains a vital tool for assessing clinical response in patients undergoing therapy and for detecting early signs of relapse.

CA 19.9 (Pancreatic Cancer Marker): This marker is specifically associated with cancers of the gastrointestinal tract, most notably pancreatic cancer. It is also used to help differentiate between cancer and other conditions, such as gallstones or cirrhosis. Tracking CA 19.9 levels provides clinicians with a biochemical roadmap of how a tumor is responding to surgical or chemical intervention.

Carcinoembryonic Antigen (CEA): CEA is a broad-spectrum tumor marker most commonly associated with colorectal cancer, though it can also be elevated in cancers of the lung, breast, and thyroid. It is particularly valuable for serial monitoring—where rising levels over time may indicate the progression of disease even before physical symptoms appear.

Tumor markers are rarely used in isolation; their true value lies in providing a comprehensive trend over time. Whether you are under clinical surveillance following a previous diagnosis or have a significant family history that requires proactive monitoring, the Serum Tumour Markers package offers the high-sensitivity data required for informed medical decision-making.